Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation?s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In June of 2016, SHINE signed a moly-99 supply agreement with HTA Co., Ltd. (HTA), the largest Chinese producer and distributor of radiopharmaceuticals. Learn more at http://shinemed.com. Mission:?SHINE Medical Technologies? is dedicated to being the world leader in safe, clean, affordable production of medical tracers and cancer treatment elements.
51 to 200 Employees
TypeCompany - Private
RevenueLess than $1 million (USD)
IndustryBiotech & Pharmaceuticals
CompetitorsUnknown
Founded2010